Experimental strategies include TROP-2 × CD3 BsAbs aiming to harness T-cell immunity against TROP-2–positive HR+ tumors and ER × CD3 constructs designed to redirect T cells toward estrogen receptor-driven cancer cells. Here, ESR1 is linked to cancer.